Deletion of braun lipoprotein and plasminogen-activating protease-encoding genes attenuates Yersinia pestis in mouse models of bubonic and pneumonic plague

Infection and Immunity

Volumn 82, Issue 6, 2014, Pages 2485-2503

  Van Lier, Christina J ^a   Sha, Jian ^a   Kirtley, Michelle L ^a   Cao, Anthony ^a   Tiner, Bethany L ^a   Erova, Tatiana E ^a   Cong, Yingzi ^a,b   Kozlova, Elena V ^a   Popov, Vsevolod L ^a   Baze, Wallace B ^c   Chopra, Ashok K ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4; LIPOPROTEIN; LIVE VACCINE; PLASMINOGEN ACTIVATING PROTEASE; PLASMINOGEN ACTIVATOR DERIVATIVE; PROTEINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; CHEMOKINE; CYTOKINE; PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BUBONIC PLAGUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EX VIVO STUDY; FEMALE; HEAT; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; LIVER INJURY; LUNG INJURY; MICROBIAL ATTENUATION; MOUSE; MUTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PLAGUE; PNEUMONIC PLAGUE; PRIORITY JOURNAL; STIMULATION; T LYMPHOCYTE ACTIVATION; WILD TYPE; YERSINIA PESTIS; ANALYSIS OF VARIANCE; ANIMAL; BACTERIAL COUNT; DISEASE MODEL; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MACROPHAGE; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PHYSIOLOGY; VIRULENCE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, BACTERIAL; CHEMOKINES; COLONY COUNT, MICROBIAL; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, BACTERIAL; LIPOPROTEINS; MACROPHAGES; MICE; PLAGUE; PLASMINOGEN ACTIVATORS; VIRULENCE; YERSINIA PESTIS;

EID: 84900389494     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01595-13     Document Type: Article

References (60)

1. Prentice MB, Rahalison L. 2007. Plague. Lancet 369:1196-1207. http://dx.doi.org/10.1016/S0140-6736(07)60566-2.
2. Huang XZ, Nikolich MP, Lindler LE. 2006. Current trends in plague research: from genomics to virulence. Clin. Med. Res. 4:189-199. http://dx.doi.org/10.3121/cmr.4.3.189.
3. Ligon BL. 2006. Plague: a review of its history and potential as a biological weapon. Semin. Pediatr. Infect. Dis. 17:161-170. http://dx.doi.org/10.1053/j.spid.2006.07.002.
4. Perry RD, Fetherston JD. 1997. Yersinia pestis-etiologic agent of plague. Clin. Microbiol. Rev. 10:35-66.
5. World Health Organization. 2006. Interregional meeting on prevention and control of plague, Antanarivo, Madagascar, 1 to 11 April. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/resources/publications/WHO_HSE_EPR_2008_3w.pdf.
6. Wagner DM, Klunk J, Harbeck M, Devault A, Waglechner N, Sahl JW, Enk J, Birdsell DN, Kuch M, Lumibao C, Poinar D, Pearson T, Fourment M, Golding B, Riehm JM, Earn DJ, Dewitte S, Rouillard JM, Grupe G, Wiechmann I, Bliska JB, Keim PS, Scholz HC, Holmes EC, Poinar H. 2014. Yersinia pestis and the Plague of Justinian 541-543 AD: a genomic analysis. Lancet Infect. Dis. 14:319-326. http://dx.doi.org/10.1016/S1473-3099(13)70323-2.
7. World Health Organization Media Center. 6 August 2009, posting date. Plague: questions and answers about plague. World Health Organization, Geneva, Switzerland. http://www.who.int/ith/diseases/plague/en/.
8. Pearson GS, Woollett GR, Chevrier MI, Tucker JB, Smithson AE. 1998. Biological weapons proliferation: reasons for concern, courses of action, p 18. Henry L. Stimson Center, Washington, DC.
9. Centers for Disease Control and Prevention. 17 November 2008, posting date. Protecting the American public by ensuring the safe and secure possession, use, and transfer of select agents and toxins that pose a threat to public health. CDC Select Agent Program, Centers for Disease Control and Prevention, Atlanta, GA. www.cdc.gov/phpr/documents/DSAT _brochure_July2011.pdf.
10. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Schoch-Spana M, Tonat K. 2000. Plague as a biological weapon. JAMA 283:2281-2290. http://dx.doi.org/10.1001/jama.283.17.2281.
11. Keeling MJ, Gilligan CA. 2000. Metapopulation dynamics of bubonic plague. Nature 407:903-906. http://dx.doi.org/10.1038/35038073.
12. Easterday WR, Kausrud KL, Star B, Heier L, Haley BJ, Ageyev V, Colwell RR, Stenseth NC. 2012. An additional step in the transmission of Yersinia pestis? ISME J. 6:231-236. http://dx.doi.org/10.1038/ismej.2011.105.
13. FDA. 2012. African green monkey (Chlorocebus aethiops) animal model development to evaluate treatment of pneumonic plague. Briefing package. FDA, Bethesda, MD. http://www.fda.gov/downloads/Advisory Committees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugs AdvisoryCommittee/UCM297180.pdf.
14. Quenee LE, Ciletti NA, Elli D, Hermanas TM, Schneewind O. 2011. Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines. Vaccine 29:6572-6583. http://dx.doi.org/10.1016/j.vaccine.2011.06.119.
15. Smiley ST. 2008. Current challenges in the development of vaccines for pneumonic plague. Expert Rev. Vaccines 7:209-221. http://dx.doi.org/10.1586/14760584.7.2.209.
16. Williamson ED, Packer PJ, Waters EL, Simpson AJ, Dyer D, Hartings J, Twenhafel N, Pitt MLM. 2011. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague. Vaccine 29:4771-4777. http://dx.doi.org/10.1016/j.vaccine.2011.04.084.
17. Smiley ST. 2008. Immune defense against pneumonic plague. Immunol. Rev. 225:256-271. http://dx.doi.org/10.1111/j.1600-065X.2008.00674.x.
18. Lin JS, Kummer LW, Szaba FM, Smiley ST. 2011. IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection. J. Immunol. 186:1675-1684. http://dx.doi.org/10.4049/jimmunol.1003303.
19. Rosenzweig JA, Jejelowo O, Sha J, Erova TE, Brackman SM, Kirtley ML, van Lier CJ, Chopra AK. 2011. Progress on plague vaccine development. Appl. Microbiol. Biotechnol. 91:265-286. http://dx.doi.org/10.1007/s00253-011-3380-6.
20. Feodorova VA, Motin VL. 2012. Plague vaccines: current developments and future perspectives. Emerg. Microbes Infect. 1:e36. http://dx.doi.org/10.1038/emi.2012.34.
21. Meyer KF. 1970. Effectiveness of live or killed plague vaccines in man. Bull. World Health Organ. 42:653-666.
22. Williamson ED, Flick-Smith HC, LeButt C, Rowland CA, Jones SM, Waters EL, Gwyther RJ, Miller J, Packer PJ, Irving M. 2005. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect. Immun. 73:3598-3608. http://dx.doi.org/10.1128/IAI.73.6.3598-3608.2005.
23. Sha J, Agar SL, Baze WB, Olano JP, Fadl AA, Erova TE, Wang S, Foltz SM, Suarez G, Motin VL, Chauhan S, Klimpel GR, Peterson JW, Chopra AK. 2008. Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. Infect. Immun. 76:1390-1409. http://dx.doi.org/10.1128/IAI.01529-07.
24. Liu T, Agar SL, Sha J, Chopra AK. 2010. Deletion of Braun lipoprotein gene (lpp) attenuates Yersinia pestis KIM/D27 strain: role of Lpp in modulating host immune response, NF-κβ activation and cell death. Microb. Pathog. 48:42-52. http://dx.doi.org/10.1016/j.micpath.2009.09.002.
25. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimpel GR, Godowski P, Zychlinsky A. 1999. Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. Science 285: 736-739. http://dx.doi.org/10.1126/science.285.5428.736.
26. Sodeinde OA, Goguen JD. 1988. Genetic analysis of the 9.5-kilobase virulence plasmid of Yersinia pestis. Infect. Immun. 56:2743-2748.
27. Lähteenmäki K, Virkola R, Sarén A, Emödy L, Korhonen TK. 1998. Expression of plasminogen activator Pla of Yersinia pestis enhances bacterial attachment to the mammalian extracellular matrix. Infect. Immun. 66:5755-5762.
28. Perry R, Fetherston J, Suomalainen M, Haiko J, Kukkonen M, Korhonen T, Lähteenmäki K, Virkola Westerlund-Wikström B, Lobo L, Ramu P. 2007. Using every trick in the book: the Pla surface protease of Yersinia pestis, p 268-278. In The genus Yersinia, vol 603. Springer, New York, NY.
29. Sodeinde OA, Subrahmanyam YV, Stark K, Quan T, Bao Y, Goguen JD. 1992. A surface protease and the invasive character of plague. Science 258:1004-1007. http://dx.doi.org/10.1126/science.1439793.
30. Sebbane F, Jarrett CO, Gardner D, Long D, Hinnebusch BJ. 2006. Role of Yersinia pestis plasminogen activator in the incidence of distinct septicemic and bubonic forms of flea-borne plague. Proc. Natl. Acad. Sci. U. S. A. 102:5526-5530. http://dx.doi.org/10.1073/pnas.0509544103.
31. Szaba FM, Smiley ST. 2002. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 99:1053-1059. http://dx.doi.org/10.1182/blood.V99.3.1053.
32. Lathem W, Price P, Miller V, Goldman W. 2007. A plasminogenactivating protease specifically controls the development of primary pneumonic plague. Science 315:509-513. http://dx.doi.org/10.1126/science.1137195.
33. Luo D, Lin JS, Parent MA, Mullarky-Kanevsky I, Szaba FM, Kummer LW, Duso DK, Tighe M, Hill J, Gruber A, Mackman N, Gailani D, Smiley ST. 2013. Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis. J. Immunol. 190:4149-4161. http://dx.doi.org/10.4049/jimmunol.1203253.
34. Caulfield AJ, Lathem WW. 2012. Substrates of the plasminogen activator protease of Yersinia pestis. Adv. Exp. Med. Biol. 954:253-260. http://dx.doi.org/10.1007/978-1-4614-3561-7_32.
35. Agar SL, Sha J, Baze WB, Erova TE, Foltz SM, Suarez G, Wang S, Chopra AK. 2009. Deletion of Braun lipoprotein gene (lpp) and curing of plasmid pPCP1 dramatically alter the virulence of Yersinia pestis CO92 in a mouse model of pneumonic plague. Microbiology 155:3247-3259. http://dx.doi.org/10.1099/mic.0.029124-0.
36. Doll JM, Zeitz PS, Ettestad P, Bucholtz AL, Davis T, Gage K. 1994. Cat-transmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. Am. J. Trop. Med. Hyg. 51:109-114.
37. Parkhill J, Wren BW, Thomson NR, Titball RW, Holden MT, Prentice MB, Sebaihia M, James KD, Churcher C, Mungall KL, Baker S, Basham D, Bentley SD, Brooks K, Cerdeño-Tárraga AM, Chillingworth T, Cronin A, Davies RM, Davis P, Dougan G, Feltwell T, Hamlin N, Holroyd S, Jagels K, Karlyshev AV, Leather S, Moule S, Oyston PC, Quail M, Rutherford K, Simmonds M, Skelton J, Stevens K, Whitehead S, Barrell BG. 2001. Genome sequence of Yersinia pestis, the causative agent of plague. Nature 413:523-527. http://dx.doi.org/10.1038/35097083.
38. Miller VL, Mekalanos JJ. 1988. A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J. Bacteriol. 170:2575-2583.
39. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U. S. A. 97:6640-6645. http://dx.doi.org/10.1073/pnas.120163297.
40. Choi KH, Schweizer H. 2005. An improved method for rapid generation of unmarked Pseudomonas aeruginosa deletion mutants. BMC Microbiol. 5:30. http://dx.doi.org/10.1186/1471-2180-5-30.
41. Edwards RA, Keller LH, Schifferli DM. 1998. Improved allelic exchange vectors and their use to analyze 987P fimbria gene expression. Gene 207: 149-157. http://dx.doi.org/10.1016/S0378-1119(97)00619-7.
42. Sha J, Fadl AA, Klimpel GR, Niesel DW, Popov VL, Chopra AK. 2004. The two murein lipoproteins of Salmonella enterica serovar Typhimurium contribute to the virulence of the organism. Infect. Immun. 72:3987-4003. http://dx.doi.org/10.1128/IAI.72.7.3987-4003.2004.
43. Sha J, Kirtley ML, van Lier CJ, Wang S, Erova TE, Kozlova EV, Cao A, Cong Y, Fitts EC, Rosenzweig JA, Chopra AK. 2013. Deletion of the Braun lipoprotein-encoding gene and altering the function of lipopolysaccharide attenuate the plague bacterium. Infect. Immun. 81:815-828. http://dx.doi.org/10.1128/IAI.01067-12.
44. Tao P, Mahalingam M, Kirtley ML, van Lier CJ, Sha J, Yeager LA, Chopra AK, Rao VB. 2013. Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines. PLoS Pathog. 9:e1003495. http://dx.doi.org/10.1371/journal.ppat.1003495.
45. Lawal A, Kirtley ML, van Lier CJ, Erova TE, Kozlova EV, Sha J, Chopra AK, Rosenzweig JA. 2013. The effects of modeled microgravity on growth kinetics, antibiotic susceptibility, cold growth, and the virulence potential of a Yersinia pestis ymoA-deficient mutant and its isogenic parental strain. Astrobiology 13:821-832. http://dx.doi.org/10.1089/ast.2013.0968.
46. Rosenzweig JA, Weltman G, Plano GV, Schesser K. 2005. Modulation of yersinia type three secretion system by the S1 domain of polynucleotide phosphorylase. J. Biol. Chem. 280:156-163. http://dx.doi.org/10.1074/jbc.M405662200.
47. Lawrence WS, Hardcastle JM, Brining DL, Weaver LE, Ponce C, Whorton EB, Peterson JW. 2009. The physiologic responses of Dutch belted rabbits infected with inhalational anthrax. Comp. Med. 59:257-265.
48. Titball RW, Williamson ED. 2001. Vaccination against bubonic and pneumonic plague. Vaccine 19:4175-4184. http://dx.doi.org/10.1016/S0264-410X(01)00163-3.
49. Kummer LW, Szaba FM, Parent MA, Adamovicz JJ, Hill J, Johnson LL, Smiley ST. 2008. Antibodies and cytokines independently protect against pneumonic plague. Vaccine 26:6901-6907. http://dx.doi.org/10.1016/j.vaccine.2008.09.063.
50. Bartra SS, Styer KL, O'Bryant DM, Nilles ML, Hinnebusch BJ, Aballay A, Plano GV. 2008. Resistance of Yersinia pestis to complementdependent killing is mediated by the Ail outer membrane protein. Infect. Immun. 76:612-622. http://dx.doi.org/10.1128/IAI.01125-07.
51. Galindo CL, Sha J, Moen ST, Agar SL, Kirtley ML, Foltz SM, McIver LJ, Kozlova EV, Garner HR, Chopra AK. 2010. Comparative global gene expression profiles of wild-type Yersinia pestis CO92 and its Braun lipovan protein mutant at flea and human body temperatures. Comp. Funct. Genomics 2010:342168. http://dx.doi.org/10.1155/2010/342168.
52. Kuby J, Kindt TJ, Goldsby RA, Osborne BA. 2007. Kuby immunology, p 396. WH Freeman & Co, San Francisco, CA.
53. DuBois AB, Freytag LC, Clements JD. 2007. Evaluation of combinatorial vaccines against anthrax and plague in a murine model. Vaccine 25:4747-4754. http://dx.doi.org/10.1016/j.vaccine.2007.03.048.
54. Anderson GW, Jr, Worsham PL, Bolt CR, Andrews GP, Welkos SL, Friedlander AM, Burans JP. 1997. Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. Am. J. Trop. Med. Hyg. 56:471-473.
55. Lukaszewski RA, Kenny DJ, Taylor R, Rees DGC, Hartley MG, Oyston PCF. 2005. Pathogenesis of Yersinia pestis infection in BALB/c mice: effects on host macrophages and neutrophils. Infect. Immun. 73:7142-7150. http://dx.doi.org/10.1128/IAI.73.11.7142-7150.2005.
56. Miossec P, Korn T, Kuchroo VK. 2009. Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361:888-898. http://dx.doi.org/10.1056/NEJMra0707449.
57. Wilke CM, Bishop K, Fox D, Zou W. 2011. Deciphering the role of Th17 cells in human disease. Trends Immunol. 32:603-611. http://dx.doi.org/10.1016/j.it.2011.08.003.
58. Ali R, Kumar S, Naqvi RA, Sheikh IA, Rao DN. 2013. Multiple antigen peptide consisting of B-and T-cell epitopes of F1 antigen of Y. pestis showed enhanced humoral and mucosal immune response in different strains of mice. Int. Immunopharmacol. 15:97-105. http://dx.doi.org/10.1016/j.intimp.2012.10.029.
59. Kamei A, Coutinho-Sledge YS, Goldberg JB, Priebe GP, Pier GB. 2011. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection. Infect. Immun. 79:1289-1299. http://dx.doi.org/10.1128/IAI.01139-10.
60. Pier GB, Meluleni G, Goldberg JB. 1995. Clearance of Pseudomonas aeruginosa from the murine gastrointestinal tract is effectively mediated by Oantigen-specific circulating antibodies. Infect. Immun. 63:2818-2825.